Aquinox Pharmaceuticals Inc. (AQXP) 7.37 $AQXP
Aquinox Pharmaceuticals (AQXP) in Focus: Stock Plunges 15.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:00AM CDT
Aquinox Pharmaceuticals has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the last day
Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND
GlobeNewswire - Mon Jun 02, 8:34AM CDT
Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced expansion of its ongoing Phase 2 clinical trials with its lead product candidate, AQX-1125.
Aquinox Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 21, 8:16AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"
(Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that David Main, Aquinox's Chief Executive Officer, will present at two upcoming investor conferences.
Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 11:58AM CDT
Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. All of the shares of common stock were offered by Aquinox. The aggregate offering price was $53.1 million, before underwriting discounts, commissions and estimated expenses. The net proceeds from the sale of the shares, after deducting the underwriting discounts, commissions and other estimated offering expenses, will be approximately $47.0 million.
Coupons.com IPO A Hot Ticket, Soars 88% On First Day
at Investor's Business Daily - Fri Mar 07, 11:24AM CST
Coupons.com (COUP) cashed in a winning ticket Friday with an initial public offering that nearly doubled on its first day of trading. The website provider of digital coupons priced at $16, above the proposed range of $12 to $14. The stock opened at...
Aquinox Pharmaceuticals Prices Initial Public Offering
GlobeNewswire - Fri Mar 07, 9:23AM CST
Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Aquinox. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AQXP". In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 630,000 additional shares of common stock at the offering price. The offering is expected to close on March 12, 2014, subject to customary closing conditions.
Aquinox Pharmaceuticals (AQXP) in Focus: Stock Plunges 15.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:00AM CDT
Aquinox Pharmaceuticals has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the last day
Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND
GlobeNewswire - Mon Jun 02, 8:34AM CDT
Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced expansion of its ongoing Phase 2 clinical trials with its lead product candidate, AQX-1125.
Aquinox Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 21, 8:16AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"
(Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that David Main, Aquinox's Chief Executive Officer, will present at two upcoming investor conferences. Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 11:58AM CDT
Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. All of the shares of common stock were offered by Aquinox. The aggregate offering price was $53.1 million, before underwriting discounts, commissions and estimated expenses. The net proceeds from the sale of the shares, after deducting the underwriting discounts, commissions and other estimated offering expenses, will be approximately $47.0 million.
Coupons.com IPO A Hot Ticket, Soars 88% On First Day
at Investor's Business Daily - Fri Mar 07, 11:24AM CST
Coupons.com (COUP) cashed in a winning ticket Friday with an initial public offering that nearly doubled on its first day of trading. The website provider of digital coupons priced at $16, above the proposed range of $12 to $14. The stock opened at...
Aquinox Pharmaceuticals Prices Initial Public Offering
GlobeNewswire - Fri Mar 07, 9:23AM CST
Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Aquinox. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AQXP". In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 630,000 additional shares of common stock at the offering price. The offering is expected to close on March 12, 2014, subject to customary closing conditions.
